Leuven, Belgium, 20 September 2018 - Oxurion NV (Euronext Brussels: OXUR - formerly known as ThromboGenics), a biopharmaceutical company developing innovative treatments to preserve vision in patients ...

Epithelial and endothelial cells expressing the primary Coxsackie virus B adenovirus (Ad) receptor (CAR) and integrin coreceptors are natural targets of human Ad infections. The fiber knob of species ...

BOSTON--(BUSINESS WIRE)--OcuTerra Therapeutics, Inc. (“OcuTerra”), a clinical stage ophthalmology company developing innovative drugs to treat ophthalmic diseases for which the current standard of ...

In a recent study published on the bioRxiv* preprint server, researchers assess the Arg-Gly-Asp (RGD) motif-mediated binding of the receptor-binding domain (RBD) of the severe acute respiratory ...

Leuven, BE, Boston, MA, US – April 7, 2021 – 05.45 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for retinal vascular ...

Topline data show that THR-687 is well-tolerated and safe. No dose-limiting toxicities or serious adverse events reported Rapid onset of action and prolonged effect on Best Corrected Visual Acuity ...

Cell adhesion to extracellular matrix components such as fibronectin has a complex basis, involving multiple determinants on the molecule that react with discrete cell surface macromolecules. Our ...

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused immense suffering and economic hardship to millions of people worldwide. To date, the mechanism of infection by SARS-CoV-2 ...

As part of its GO™ Peptides collection, AnaSpec has introduced a selection of cyclic and non-cyclic RGD peptides. The RGD (Arg-Gly-Asp) tripeptide motif can be found in extracellular matrix (ECM) ...

Scientists from the Mechanobiology Institute, Singapore (MBI) at the National University of Singapore have discovered the universal building blocks that cells use to form initial connections with the ...

Oxurion NV – Publication in Progress in Retinal Eye Research highlights the potential of pan-RGD integrin antagonists to improve the treatment of diabetic retinopathy and wet AMD Oxurion is a leader ...